Assembly Biosciences, Inc. (ASMB)
NASDAQ: ASMB · Real-Time Price · USD
27.06
-0.46 (-1.67%)
At close: Apr 28, 2026, 4:00 PM EDT
27.00
-0.06 (-0.22%)
After-hours: Apr 28, 2026, 4:00 PM EDT
Assembly Biosciences Employees
Assembly Biosciences had 73 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
73
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$990,452
Profits / Employee
-$83,863
Market Cap
429.24M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Ginkgo Bioworks Holdings | 485 |
| REGENXBIO | 371 |
| Entrada Therapeutics | 152 |
| Neurogene | 131 |
| Lexeo Therapeutics | 59 |
| Atea Pharmaceuticals | 55 |
| Contineum Therapeutics | 51 |
| Eupraxia Pharmaceuticals | 49 |
ASMB News
- 19 days ago - Assembly Biosciences Highlights Presentations on Positive Phase 1b Data for ABI-5366 and ABI-1179 in Recurrent Genital Herpes at ESCMID Global 2026 - GlobeNewsWire
- 5 weeks ago - Assembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights - GlobeNewsWire
- 4 months ago - Gilead Sciences Exercises Option to License Assembly Biosciences' Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes - Business Wire
- 5 months ago - Assembly Biosciences Transcript: Study Result - Transcripts
- 5 months ago - Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rate in Recurrent Genital Herpes - GlobeNewsWire
- 5 months ago - Assembly Biosciences Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference - Transcripts
- 6 months ago - Assembly Biosciences Reports Third Quarter 2025 Financial Results and Recent Updates - GlobeNewsWire
- 6 months ago - Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The Liver Meeting® - GlobeNewsWire